To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

Also called NCT03261375

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 205 participants (enrolled count) (from the registry)
Sponsor
Shanghai Golden Leaf MedTec Co. Ltd (from the registry)
Registry
  • NCT NCT03261375
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03261375. Randomized; double masking; primary purpose treatment. Start 2021-01-19 (actual); primary completion 2022-12-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension
Condition
Hypertension
Intervention (Device)
Renal Artery Radiofrequency Ablation System (Generator and Catheter )
Intervention (Drug)
Antihypertensive Agents
Intervention (Device)
Sham Procedure
Lead sponsor
Shanghai Golden Leaf MedTec Co. Ltd (class: industry)

Record details

Record id
cardio:ct-nct03261375
Content hash
0e4954e488a3432947524f77039710fad227a85dfc20c4050f94dea3f9da9ee6